2-(3-氯苯基)-6-硝基-1H-苯并咪唑 | 1571-88-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 2-(3-氯苯基)-6-硝基-1H-苯并咪唑
• 英文名称: 2-(3-chlorophenyl)-5-nitro-1H-benzo[d]imidazole
• 英文别名: 2-(3-chlorophenyl)-6-nitro-1H-benzimidazole
• CAS: 1571-88-6
• 化学式: C₁₃H₈ClN₃O₂
• 分子量: 273.678
• InChiKey: OOQZMPRTANLIOC-UHFFFAOYSA-N

物化性质

• 熔点：
  215 °C
• 沸点：
  515.5±56.0 °C(Predicted)
• 密度：
  1.485±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  74.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(3-氯苯基)-6-硝基-1H-苯并咪唑 在 铁粉 、 溶剂黄146 作用下， 以 乙醇 、 水 、 异丙醇 为溶剂， 反应 7.0h， 生成 N-(2-(3-chlorophenyl)-1H-benzo[d]imidazol-6-yl)quinazolin-4-amine
  参考文献：
  名称：

  Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2

  摘要：

  Both c-Met and VEGFR-2 are important targets for the treatment of cancers. In this study, a series of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinazolin-4-amine derivatives were designed and identified as dual c-Met and VEGFR-2 inhibitors. Among these compounds bearing quinazoline and benzimidazole fragments, compound 7j exhibited the most potent inhibitory activity against c-Met and VEGFR-2 with IC50 of 0.05μM and 0.02μM, respectively. It also showed the highest anticancer activity against the tested cancer cell lines with IC50 of 1.5μM against MCF-7 and 8.7μM against Hep-G2. Docking simulation supported the initial pharmacophoric hypothesis and suggested a common mode of interaction at the ATP-binding site of c-Met and VEGFR-2, which demonstrates that compound 7j is a potential agent for cancer therapy deserving further researching.

  DOI：

  10.1016/j.bmc.2014.07.008
• 作为产物：
  描述：

  4-硝基邻苯二胺 、 3-氯苯甲酸 在 polyphosphoric acid (PPA) 作用下， 反应 5.0h， 以83%的产率得到2-(3-氯苯基)-6-硝基-1H-苯并咪唑
  参考文献：
  名称：

  的发现ñ - （2-苯基- 1 H ^ -苯并[ d ]咪唑-5-基）喹啉-4-胺衍生物是新颖的VEGFR-2激酶抑制剂

  摘要：

  抑制VEGF信号传导途径已成为治疗癌症的有价值的方法。在这项工作中，设计了一系列N-（2-苯基-1 H-苯并[ d ]咪唑-5-基）喹啉-4-胺衍生物并将其鉴定为VEGFR-2（KDR）激酶的有效抑制剂。合成了具有喹啉骨架和苯并咪唑部分的这些化合物，并评估了它们对VEGFR-2和两种人类癌细胞系的生物学活性。其中，化合物7s对VEGFR-2的抑制作用最强，IC 50为0.03μM，对受试癌细胞系的IC 50表现出最高的抗癌活性。针对MCF-7为1.2μM，针对Hep-G2为13.3μM。对接模拟支持最初的药效学假说，并提出了在VEGFR-2 ATP结合位点的共同相互作用方式，这表明化合物7s是潜在的癌症治疗药物，值得进一步研究。

  DOI：

  10.1016/j.ejmech.2014.07.071

文献信息

• Discovery of a Novel Mycobacterial F‐ATP Synthase Inhibitor and its Potency in Combination with Diarylquinolines
  作者：Adam Hotra、Priya Ragunathan、Pearly Shuyi Ng、Pattarakiat Seankongsuk、Amaravadhi Harikishore、Jickky Palmae Sarathy、Wuan‐Geok Saw、Umayal Lakshmanan、Patcharaporn Sae‐Lao、Nitin Pal Kalia、Joon Shin、Revathy Kalyanasundaram、Sivaraj Anbarasu、Krupakar Parthasarathy、Chaudhari Namrata Pradeep、Harshyaa Makhija、Peter Dröge、Anders Poulsen、Jocelyn Hui Ling Tan、Kevin Pethe、Thomas Dick、Roderick W. Bates、Gerhard Grüber

  DOI：10.1002/anie.202002546

  日期：2020.8.3

  that GaMF1 inhibits ATP synthase activity by binding to the loop. GaMF1 is bactericidal and is active against multidrug‐ as well as bedaquiline‐resistant strains. Chemistry efforts on the scaffold revealed a dynamic structure activity relationship and delivered analogues with nanomolar potencies. Combining GaMF1 with bedaquiline or novel diarylquinoline analogues showed potentiation without inducing genotoxicity

  F 1 F O -ATP合酶是结核分枝杆菌生长和生存力所必需的并且是经过验证的临床目标。酶旋转γ亚基的分枝杆菌特异性环在酶复合物中ATP合成的偶联中起作用。我们报告发现了针对这种γ亚基环的新型抗分枝杆菌GaMF1的发现。生化和NMR研究表明，GaMF1通过与环结合来抑制ATP合酶活性。GaMF1具有杀菌作用，对多药耐药和苯达喹啉耐药菌株具有活性。在支架上的化学努力揭示了动态结构活性关系，并提供了具有纳摩尔浓度的类似物。GaMF1与苯达喹啉或新型二芳基喹啉类似物的结合在人胚胎干细胞报告基因分析中显示出增强作用，而不会引起基因毒性或表型变化。
• Visible light promoted tandem dehydrogenation-deaminative cyclocondensation under aerobic conditions for the synthesis of 2-aryl benzimidazoles/quinoxalines from <i>ortho</i>-phenylenediamines and arylmethyl/ethyl amines
  作者：Firdoos Ahmad Sofi、Rohit Sharma、Ravi Rawat、Asit K. Chakraborti、Prasad V. Bharatam

  DOI：10.1039/d0nj03002c

  日期：——

  Visible light promoted domino synthesis of 2-aryl benzimidazoles is reported through the reaction of ortho-phenylenediamines and arylmethyl amines under aerobic conditions. The methodology has wide substrate scope and tolerates a wide range of functional groups affording the products in high yields. The use of arylethyl amines instead of arylmethyl amines gives 2-aryl quinoxalines.

  据报道，通过有氧条件下邻苯二胺与芳基甲基胺的反应，可见光促进了2-芳基苯并咪唑的多米诺骨牌合成。该方法具有广泛的底物范围，并且可以耐受多种官能团，从而以高收率提供了产品。使用芳基乙基胺代替芳基甲基胺得到2-芳基喹喔啉。
• [EN] COMPOUNDS FOR TREATING TUBERCULOSIS<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE LA TUBERCULOSE
  申请人：UNIV NANYANG TECH

  公开号：WO2021107876A1

  公开（公告）日：2021-06-03

  The invention concerns a compound of formula (Ia) or (Ib) wherein R1 is hydrogen or a methyl group; R2 is an unsubstituted or substituted alkyl group; R3 is an aryl group or a heteroaryl group, optionally substituted by one or more groups selected from halogen, alkyl or alkoxy; and, in Formula (Ia), X is CH or N and Y is NH, S or O, or, in Formula (Ib), X is NH, S or O and Y is CH or N. The invention further concerns a method of synthesizing the inventive compound, a composition comprising the inventive compound or a pharmaceutically acceptable salt thereof and bedaquiline (BDQ), an analogue of bedaquiline (BDQ) or a mixture thereof, and the use of said composition or compound for the treatment of tuberculosis.

  该发明涉及一种化合物，其化学式为(Ia)或(Ib)，其中R1为氢或甲基基团；R2为未取代或取代的烷基基团；R3为芳基或杂环芳基，可选择地被卤素、烷基或烷氧基中的一个或多个基团取代；在化学式(Ia)中，X为CH或N，Y为NH、S或O；或在化学式(Ib)中，X为NH、S或O，Y为CH或N。该发明还涉及一种合成该创新化合物的方法，包括该创新化合物或其药学上可接受的盐以及贝达替林（BDQ）、贝达替林（BDQ）的类似物或二者混合物的组合物，以及使用该组合物或化合物用于治疗结核病。
• IMIDAZOLE DERIVATIVES HAVING ARYL PIPERIDINE SUBSTITUENT, METHOD FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
  申请人：Suh Jee Hee

  公开号：US20100145054A1

  公开（公告）日：2010-06-10

  The present invention is directed to a novel imidazole derivative having an aryl piperidine substituent of formula (I) and a method for preparation thereof, and a pharmaceutical composition containing said imidazole derivative as an active ingredient for preventing or treating a MCH (melanine-concentrating hormone)-related disease.

  本发明涉及一种具有式(I)的芳基哌啶取代基的新型咪唑衍生物及其制备方法，以及含有该咪唑衍生物作为活性成分的药物组合物，用于预防或治疗与MCH（黑色素浓集激素）相关的疾病。
• Derivatives of 2-Phenylbenzimidazole. II
  作者：George Sandera、Robert W. Isensee、Lionel Joseph

  DOI：10.1021/ja01649a066

  日期：1954.10